CORRECTION Open Access

Correction: Early sevoflurane sedation in severe COVID19-related lung injury patients. A pilot randomized controlled trial

Beatrice Beck-Schimmer^{1,2}, Erik Schadde^{2,3}, Urs Pietsch⁴, Miodrag Filipovic⁴, Seraina Dübendorfer-Dalbert⁵, Patricia Fodor⁵, Tobias Hübner⁶, Reto Schuepbach⁷, Peter Steiger⁷, Sascha David⁷, Bernard D. Krüger¹, Thomas A. Neff⁶ and Martin Schläpfer^{1,2*}

Correction: Annals of Intensive Care (2024) 14:41 https://doi.org/10.1186/s13613-024-01276-4

In Table 2 of this article [1], the data in the [Primary endpoint reached, n (%)] headed **Sevoflurane**, should be listed as 11 (39) not 11 (16).

Primary Endpoint Reached, it reads, that 11 patients in the sevoflurane and 13 in the propofol group reached the primary endpoint. This is correct, but the percentages are incorrect, they should be 39 and 41%, respectively.

Table 2 Primary and secondary outcomes (uncorrected)

Variable	Sevoflurane	Control	p-value
Primary outcome	n=28	n=32	
Primary endpoint reached, n (%)	11 (16)	13 (41)	0.916

The original article can be found online at https://doi.org/10.1186/s13613-024-01276-4.

*Correspondence:

Martin Schläpfer

martin.schlaepfer@uzh.ch

¹ Institute of Anesthesiology, University Hospital Zurich University of Zurich, Raemistrasse 100, 8091 Zurich, Switzerland

² Institute of Physiology, University of Zurich, Zurich, Switzerland

³ Department of Surgery, Rush University, Chicago, IL, USA

⁴ Division of Anesthesiology, Intensive Care, Rescue and Pain Medicine, Cantonal Hospital St. Gallen, St. Gallen, Switzerland

⁵ Institute of Anesthesia and Intensive Care Medicine, City Hospital Triemli, Zurich, Switzerland

⁶ Department of Anesthesia and Intensive Care Medicine, Cantonal Hospital Muensterlingen, Muensterlingen, Switzerland

⁷ Institute of Intensive Care Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland

Variable	Sevoflurane	Control	p-value
Death, n (%)	5 (16)	5 (18)	0.817
Survivors	n=23	n=27	

2: Primary and secondary outcomes (corrected)

Variable	Sevoflurane	Control	p-value	
Primary outcome	n=28	n=32		
Primary endpoint reached, n (%)	11 (39)	13 (41)	0.916	
Death, n (%)	5 (16)	5 (18)	0.817	
Survivors	n=23	n = 27		

The original article has been corrected.

Published online: 16 June 2024

Reference

 Beck-Schimmer B, Schadde E, Pietsch U, Filipovic M, Dübendorfer-Dalbert S, Fodor P, Hübner T, Schuepbach R, Steiger P, David S, Krüger BD, Neff TA, Schläpfer M. Early sevoflurane sedation in severe COVID19-related lung injury patients. A pilot randomized controlled trial. Ann Intensive Care. 2024;14:41. https://doi.org/10.1186/s13613-024-01276-4.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.